Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 454-459

  Akins, R L ^a   Rybak, M J ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GLYCOPEPTIDE; METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DISEASE SIMULATION; DRUG HALF LIFE; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MICROBIAL; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; HALF-LIFE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0035144849     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.454-459.2001     Document Type: Article

References (18)

1. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model
2. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin
3. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium
4. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium
5. Summary of notifiable diseases, United States
6. 2+ and albumin on these drugs
7. Recommendations for preventing the spread of vancomycin resistance
8. Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once-daily or thrice-daily against Enterococcus faecalis in an in vitro infection model
9. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis
10. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin
11. Effect of protein binding of daptomycin on MIC and antibacterial activity
12. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus
13. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia
14. Clinical evaluation of teicoplanin fluorescence polarization immunoassay
15. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus
16. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides
17. Vancomycin-resistant Staphylococcus aureus: Infection control considerations